Selected Reports from the Digestive Disease Week (Liver Conference)

NATAP
Reports

Highlights from
Digestive Disease Week
Liver Conference

May 20-23, 2001
Atlanta, Georgia

L-DT: New Hepatitis B Drug
L-DT: An Ongoing Phase I/IIA Dose-Escalation Trial In Patients with Chronic HBV Infection (NV-02B-001)
(8/8/01)
Herb Reports at DDW (CH100)
(8/7/01)
Treating Hepatitis C in Recovering Injection Drug Users on Methadone
(8/3/01)
Predictive Value of Alt Levels On Histological Findings In Chronic Hepatitis C: A European Collaborative Study
(8/2/01)
Independent Predictors of Severe Liver Fibrosis in Chronic Hepatitis C
(8/2/01)
HCV & Pregnancy, risk factors for transmission: breastfeeding, c-section, use of forceps in delivery
     C-Section May Reduce HCV Transmission ...>
     Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network ...>
     Mother To Child Transmission of HCV: a case control study of risk factors; use of forceps during vaginal delivery found to increase risk of transmission, as in HIV ...>
(8/1/01)
Impact of Hiv Infection On Health-Related Quality of Life In Patients with Chronic Hepatitis C: An Unexpected Finding
(8/1/01)
High Dose Induction Therapy With Consensus Interferon Followed By Combination Therapy With Ribavirin For Treatment-Naive Hepatitis C Patients
(8/1/01)
Diet and Hepatitis C
Written for NATAP by Jocelyn Rodriguez
(8/1/01)
Hepatic Iron Accumulation Is An Independent Risk Factor For The Development Of Hepatocellular Carcinoma After Interferon Therapy In Patients With Chronic Hepatitis C
(8/1/01)
Platelet Counts; Elevated Lipids; Thymosin alpha-1 for HBV; treating HCV in
methadone, psychiatric, and former drug users, Hepatotoxicity in HIV in the
ACTG
-- Platelet Count May Predict HCV Liver Disease Progression ..>
-- Elevated Cholesterol/Triglycerides May Be Associated With Accelerated Liver Disease Progression; Treatment May Slow Progression ..>
-- Meta-Analysis of Thymosin Alpha Treatment for Hepatitis B ..>
-- Thymosin Alpha for Treatment of Hepatitis B ..>
-- Psychiatric Patients, Methadone Patients, and Earlier Drug Users Can Be Treated for HCV When Given Adequate Support Services ..>
-- Hepatotoxicity in the US Adult Clinicals Trials Group ..>
(7/11/01)
Does HAART Affect Liver Disease Progression in HCV/HIV Coinfected Patients?
(7/11/01)
Patient's Ability to Mount an Immune Response Appears Associated with Response to HCV Therapy
(7/9/01)
Preliminary study Results Show HCV in Blood Reflects HCV in Liver Cells
(7/9/01)
Study of Treatment for HCV Following Recurrence of HCV After Liver Transplant
(7/9/01)
Predicting Response to HCV Therapy After One Day of Inteferon
(7/9/01)
Two Studies Find Benefit in Treating HCV During Acute Infection
(7/9/01)
Aerosol Liposomal IL-2 Combined with Interferon+Ribavirin in Patients Who Previously Failed Interferon+Ribavirin
(6/24/01)
Anemia When Taking Interferon + Ribavirin and EPO Therapy for Anemia
(6/24/01)
Pegasys + Ribavirin
Pegylated (40kDa) Interferon Alfa-2a (Pegasys) in Combination With Ribavirin: efficacy and Safety Results From a Phase III Randomized, Actively Controlled Multicenter Study
(5/23/01)
Treatment of Chronic Hepatitis C Virus (HCV) In the Inmate Setting: Does Compliance Effect Response in African-Americans (AA)?
(5/22/01)
PEG IFN/RBV in Relapsers & Nonresponders
Combination IFN/RBV Viral load nonresponders do not respond when treated again, but preliminary data shown at DDW suggests they may respond to pegylated interferon plus RBV.
(5/22/01)

< www.natap.org

to top

All other Conferences >